教育背景
工作經歷
2006-07~2008-08,中國科學院上海藥物研究所, 助理研究員
2001-09~2006-06,中國科學院上海藥物研究所, 博士
1993-09~1998-06,上海醫科大學, 大學本科
社會兼職
研究方向
抗腫瘤創新藥物的發現和作用機理研究
1.利用分子、細胞和動物模型開展新型抗腫瘤藥物的發現和研究
2.以抗腫瘤化合物為探針開展抗腫瘤作用新機理及新靶標的發現和研究
招生專業
100706-藥理學
招生方向
腫瘤藥理
近期成果
2023年12月16日,
臨港實驗室謝成英研究團隊聯合上海科技大學免疫化學研究所免疫化學生物學課題組在國際學術期刊
Experimental Hematology & Oncology上發表題為“Targeting ST8SIA6-AS1 counteracts KRASinhibitor resistance through abolishing the reciprocal activation of PLK1/c-Myc signaling”的研究論文。該研究報導了針對KRAS突變腫瘤治療的新型耐藥機制,提出了克服耐藥的新策略。
代表論文
(1) Chengying Xie#, Huajun Zhao#, Xubin Bao, Haoyu Fu, and Liguang Lou*. Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist. J Cell Mol Med. 2018; 22(11):5367-5377.
(2) Chengying Xie, Xiaozhe Wan, Haitian Quan, Mingyue Zheng, Li Fu, Yun Li, and Liguang Lou*. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci. 2018;109(4):1207-1219.
(3) Chengying Xie, Xiangling Chen, Mingyue Zheng, Xiaohong Liu, Hongbin Wang, and Liguang Lou*. Pharmacologic characterization of SHR8443, a novel dual inhibitor of phosphatidylinositol 3-kinase and mammalian target of rapamycin. Oncotarget. 2017; 8(64):107977-107990.
(4) Chengying Xie, Ye He, Mingyue Zheng, Yulan Wang,Yongping Xu, and Liguang Lou. Puquitinib, a novel orally available PI3Kδ inhibitor, exhibits potent antitumor efficacy against acute myeloid leukemia. Cancer Sci. 2017;108(7):1476-1484.
(5) Xiangling Chen, Peng Liu, Quanren Wang, Yun Li, Li Fu, Haoyu Fu, Jianming Zhu, Zhaoqiang Chen, Weiliang Zhu*, Chengying Xie*, and Liguang Lou*. DCZ3112, a novel Hsp90 inhibitor, exerts potent antitumor activity against HER2-positive breast cancer through disruption of Hsp90-Cdc37 interaction. Cancer Lett. 2018;434: 70-80.
(6) Ye He, Liping Sun, Yongping Xu, Li Fu, Yun Li, Xubin Bao, Haoyu Fu, Chengying Xie*, and Liguang Lou*. Combined inhibition of PI3Kδ and FLT3 signaling exerts synergistic antitumor activity and overcomes acquired drug resistance in FLT3-activated acute myeloid leukemia. Cancer Lett. 2018;420: 49-59.
(7) Zhihui Zhu, Chenghua Lou, Zhiguo Zheng, Rui Zhu, Shasha Tian, Chengying Xie*, and Huajun Zhao*. ZFP403, a novel tumor suppressor, inhibits the proliferation and metastasis in ovarian cancer. Gynecol Oncol. 2017; 174(2):418-425.
(8) Mingzhao Gao, Hongbin Wang, Xiangling Chen, Wenting Cao, Li Fu, Yun Li, Hatian Quan, Chengying Xie*, and Liguang Lou*. Aberrant modulation of riosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma. Acta Pharmacol Sin. 2018;18.doi: 10.1038/s41401-018-0020-z. [Epub ahead of print]
(9) Zhixin Zhao, Jianming Zhu, Haitian Quan, Guimin Wang, Bo Li, Weiliang Zhu*, Chengying Xie*, and Liguang Lou*. X66, a novel N-terminal heat shock protein 90 inhibitor, exerts antitumor effects without induction of heat shock response. Oncotarget. 2016;7(20):29648-29663.
科研項目
( 1 ) 以EGFR、KDR、HER2、VEGFR為靶點的抗腫瘤創新藥物藥效學研究, 主持, 研究所(學校), 2009-11--2020-11
( 2 ) 同時靶向癌細胞能量代謝和DNA複製的新型鉑類配合物設計、合成和抗腫瘤作用研究, 參與, 國家級, 2012-01--2015-12
( 3 ) PI3K抑制劑XC-302的抗腫瘤作用機理研究, 主持, 國家級, 2009-01--2011-12
( 4 ) 新型Hsp90抑制劑X66抗腫瘤作用分子機理研究, 主持, 國家級, 2013-01--2016-12